Axonics Modulation Technologies Inc (AXNX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
AXNX Chart
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
Axonics Modulation Technologies Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AAL Avraham A. Levitan Glass Jacobson Investment Advisors LLC | 5,951 | $342,835.8 | $414,190 | $71,354.2 | 20.81% |
Axonics Modulation Technologies Inc (AXNX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Axonics Modulation Technologies Inc Profile
| - Industry | - Sector | Mr. Raymond W. Cohen CEO | NASDAQ (NGS) Exchange | 05465P101 CUSIP |
| United States Country | 797 Employees | - Last Dividend | - Last Split | 31 Oct 2018 IPO Date |
Overview
Axonics, Inc. is a pioneering medical technology company focused on the development, commercialization, and innovation of advanced products aimed at treating bladder and bowel dysfunctions. With a core emphasis on sacral neuromodulation (SNM) systems, Axonics, Inc. offers groundbreaking solutions for patients suffering from overactive bladder (OAB), fecal incontinence (FI), and non-obstructive urinary retention (UR). The company's inception dates back to 2012, under the name Axonics Modulation Technologies, Inc., before rebranding to Axonics, Inc. in March 2021. Headquartered in Irvine, California, Axonics, Inc. has established a significant global presence, reaching patients through direct sales forces and distributors across the United States, United Kingdom, Germany, the Netherlands, Nordic countries, and various international markets.
Products and Services
- Sacral Neuromodulation (SNM) Systems
- Bulkamid
Axonics, Inc.’s flagship SNM systems are designed to alleviate symptoms associated with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, fecal incontinence (FI), and non-obstructive urinary retention (UR). These treatments stand out by delivering mild electrical pulses to the sacral nerve, aiming to restore normal brain communication and reduce symptoms. The company provides both rechargeable (R20) and recharge-free (F15) implantable SNM systems to cater to diverse patient needs.
As part of its broader commitment to addressing urinary health, Axonics, Inc. offers Bulkamid, a urethral bulking agent specifically designed for the treatment of female stress urinary incontinence. This innovative solution represents the company’s stride towards expanding its product portfolio to include non-electronic therapeutic options, further illustrating its dedication to improving patient outcomes across a range of urinary incontinence issues.
